Clinical Trial Update: A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating Gliadel implants followed by bevacizumab (Avastin) and irinotecan for glioblastoma multiforme was terminated, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Gliosarcoma
• Malignant Glioma

Drugs mentioned

• Avastin (bevacizumab)
• Camptosar (irinotecan)
• GLIADEL (Carmustine)

Snippet

Sponsor: Duke University | Conditions: Malignant Glioma, Glioblastoma Multiforme | Phase 2 | Status: TERMINATED | Results posted: 2013-02-04